OncoResponse utilizes a clinically validated technology platform to discover authentic human antibodies to multiple high value targets associated with immunosuppressive myeloid biology. The company focuses on leveraging elite immune responses to develop novel cancer immunotherapies aimed at enhancing the effectiveness of immunotherapy.

OncoResponse utilizes a clinically validated technology platform to discover authentic human antibodies to multiple high value targets associated with immunosuppressive myeloid biology. The company focuses on leveraging elite immune responses to develop novel cancer immunotherapies aimed at enhancing the effectiveness of immunotherapy.